**Supplementary Data.** Exclusion Criteria for Select Ongoing Clinical Trials Examining Shorter Multidrug-resistant Tuberculosis (MDR-TB)/Extensively Drug-Resistant (XDR) Treatment Regimens

**Stage 1 of the STREAM (Evaluation of a Standard Treatment Regimen of Anti-TB Drugs for Patients with MDR-TB) trial1**

Excluded

* <18 years of age
* *Mycobacterium tuberculosis* resistance to fluoroquinolones or second-line injectable drugs
* Human Immunodeficiency Virus (HIV) infection and CD4 counts <50/mm3
* History of alcohol or drug abuse
* TB meningitis or bone/joint TB

Included

* *Mycobacterium tuberculosis* resistance to patients with pyrazinamide or ethambutol resistance

**NIX\* (New Investigational Drugs for XDR TB) trial2**

Excluded

* <14 years of age
* Patients whose well-being might have been compromised (e.g., persons with uncontrolled diabetes, cardiomyopathy, or extrapulmonary TB requiring extended treatment)

Included

* XDR pulmonary tuberculosis, or treatment-intolerant or non-responsive MDR TB

\* Regimen of three novel medications with little or no known resistance (bedaquiline, pretomanid, linezolid)

1. The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB (STREAM); updated 2018 Jan 26. Available at: <https://clinicaltrials.gov/ct2/show/NCT02409290?term=NCT02409290&rank=1>. Accessed 2018 August 15.

2. A Phase 3 Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis; updated 2018 May 18. Available at: <https://clinicaltrials.gov/ct2/show/NCT02333799>. Accessed 2018 August 15.